SCHEMBL6941296

SCHEMBL6941296

CC(C)(C)OC(=O)N(Cc1cc(C(=O)O)ccc1N)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 1/20 0.42
KDM4E B2RXH2 5/20 0.39
GAA P10253 5/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
THRB P10828 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
GFER P55789 1/20 0.38
PLEC Q15149 1/20 0.38
PTGER4 P35408 1/20 0.37
LMNA P02545 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
GRM2 Q14416 1/20 0.35
HSD17B10 Q99714 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6948372 0.89 ALOX15 (0.42) KDM4EGAAALDH1A1MAPTHPGD
SCHEMBL2174682 0.86 MRGPRX4 (0.43) ALDH1A1RAB9AHTTLMNAHDAC3
SCHEMBL12569696 0.84 PRKCI (0.38) GAAALDH1A1MAPTTHRBGRM2
SCHEMBL29853425 0.83 GRM2 (0.36) MAPTSMN1; SMN2THRBHTTGRM2
SCHEMBL7425320 0.82 KDM4E (0.38) CDC25BKDM4EGAAALDH1A1MAPT
SCHEMBL8326411 0.82 LPAR1 (0.38) CDC25BKDM4EGAAALDH1A1MAPT
SCHEMBL8326453 0.82 CDC25B (0.37) CDC25BKDM4EGAAALDH1A1MAPT
SCHEMBL6392687 0.82 ACE2 (0.36) MAPTSMN1; SMN2HDAC3HDAC1HDAC2
SCHEMBL5191856 0.82 GRM2 (0.45) HDAC1HDAC2GRM2
SCHEMBL6950389 0.82 POLB (0.49) LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946180-A4 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORP (US) 2003-07-23 EP disclosed
EP-0767792-A4 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-11-20 EP disclosed
US-20020032187-A1 Method for stimulating bone formation SMITHKLINE BEECHAM CORPORATION 2002-03-14 US disclosed
US-5977101-A Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity SMITHKLINE BEECHAM CORPORATION (US) 1999-11-02 US disclosed
EP-0946180-A1 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORPORATION (US) 1999-10-06 EP disclosed
WO-1998015278-A1 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORPORATION (US) 1998-04-16 WO disclosed
EP-0767792-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-04-16 EP disclosed
WO-1996000730-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032187-A1 Method for stimulating bone formation BMP2, BMP4, SOST CDC25B 1434/4885KDM4E 4199/4885GAA 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.